CN105999085A - Pharmaceutical composition for curing cervicitis and preparation method and application of pharmaceutical composition - Google Patents
Pharmaceutical composition for curing cervicitis and preparation method and application of pharmaceutical composition Download PDFInfo
- Publication number
- CN105999085A CN105999085A CN201610516572.4A CN201610516572A CN105999085A CN 105999085 A CN105999085 A CN 105999085A CN 201610516572 A CN201610516572 A CN 201610516572A CN 105999085 A CN105999085 A CN 105999085A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- extracting solution
- weight
- pharmaceutical composition
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 55
- 206010008323 cervicitis Diseases 0.000 title claims abstract description 27
- 208000006374 Uterine Cervicitis Diseases 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 90
- 239000000843 powder Substances 0.000 claims abstract description 41
- 241000131808 Scolopendra Species 0.000 claims abstract description 39
- 239000000341 volatile oil Substances 0.000 claims abstract description 37
- 239000003921 oil Substances 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 67
- 239000000284 extract Substances 0.000 claims description 46
- 241000628997 Flos Species 0.000 claims description 42
- 229940079593 drug Drugs 0.000 claims description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 239000000829 suppository Substances 0.000 claims description 32
- 239000012141 concentrate Substances 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 13
- 239000000469 ethanolic extract Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 7
- -1 effervescent Substances 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 239000003595 mist Substances 0.000 claims 1
- 230000003628 erosive effect Effects 0.000 abstract description 11
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 10
- 238000002474 experimental method Methods 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 5
- 239000012567 medical material Substances 0.000 abstract description 3
- 241000205585 Aquilegia canadensis Species 0.000 abstract 2
- 240000009138 Curcuma zedoaria Species 0.000 abstract 2
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract 2
- 235000014220 Rhus chinensis Nutrition 0.000 abstract 2
- 240000003152 Rhus chinensis Species 0.000 abstract 2
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract 2
- 239000010681 turmeric oil Substances 0.000 abstract 2
- 235000019509 white turmeric Nutrition 0.000 abstract 2
- 239000000243 solution Substances 0.000 description 67
- 241000700159 Rattus Species 0.000 description 20
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 210000001215 vagina Anatomy 0.000 description 11
- 238000003756 stirring Methods 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 8
- 210000003679 cervix uteri Anatomy 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 235000019640 taste Nutrition 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 206010008342 Cervix carcinoma Diseases 0.000 description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 5
- 240000008042 Zea mays Species 0.000 description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 201000010881 cervical cancer Diseases 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 235000005822 corn Nutrition 0.000 description 5
- 229960002986 dinoprostone Drugs 0.000 description 5
- 210000002683 foot Anatomy 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 240000001307 Myosotis scorpioides Species 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 230000004856 capillary permeability Effects 0.000 description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
- 239000007938 effervescent tablet Substances 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 238000002481 ethanol extraction Methods 0.000 description 4
- 125000005456 glyceride group Chemical group 0.000 description 4
- 229940075507 glyceryl monostearate Drugs 0.000 description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 201000003988 chronic cervicitis Diseases 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- 244000178320 Vaccaria pyramidata Species 0.000 description 2
- 235000010587 Vaccaria pyramidata Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 201000005630 leukorrhea Diseases 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 2
- 229960004659 ticarcillin Drugs 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 206010046901 vaginal discharge Diseases 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 244000235603 Acacia catechu Species 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 241001674345 Callitropsis nootkatensis Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008254 Cervical cyst Diseases 0.000 description 1
- 241000258920 Chilopoda Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000576429 Forsythia suspensa Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- BPYGTFFYYOWDBC-LOVSFRALSA-N arctiin Natural products COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc3ccc(O[C@@H]4O[C@H](C)[C@@H](O)[C@H](O)[C@H]4O)c(OC)c3)cc1OC BPYGTFFYYOWDBC-LOVSFRALSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 229940038649 clavulanate potassium Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000016369 nabothian cyst Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- ABVRVIZBZKUTMK-JSYANWSFSA-M potassium clavulanate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 ABVRVIZBZKUTMK-JSYANWSFSA-M 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 229910052957 realgar Inorganic materials 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/648—Myriapods, e.g. centipedes or millipedes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to pharmaceutical composition for curing cervicitis and a preparation method and application of the pharmaceutical composition. The pharmaceutical composition comprises zedoary turmeric oil, fine powder and pharmaceutically acceptable auxiliary materials. The zedoary turmeric oil and the fine powder are prepared from the following raw medical materials of honeysuckle flower, fructus forsythiae, cortex phellodendri, radix arnebiae seu lithospermi, rhizoma curcumae, scolopendra, rhizoma bletillae and Chinese gall according to following steps. The steps comprise extracting oil of the rhizoma curcumae to obtain volatile oil and an extracting solution a and combining the extracting solution a with an aqueous alcohol extracting solution b of the cortex phellodendri, the honeysuckle flower and the radix arnebiae seu lithospermi and an aqueous extracting solution c of the scolopendra, the fructus forsythiae, the Chinese gall and the rhizoma bletillae. Experiments show that the pharmaceutical composition has a good curative effect on cervical erosion and a good anti-inflammatory effect.
Description
Technical field
The present invention relates to one and treat anti-inflammatory drugs compositions and preparation method and application, specifically refer to one and treat son
Pharmaceutical composition of cervicitis and preparation method and application.
Background technology
Cervicitis is common gynaecopathia, has leucorrhoea grow in quantity, waist stomachache and the symptom such as lumbosacral region discomfort or menoxenia,
With the passing of time, if do not noted, pathogen such as streptococcus, staphylococcus, escherichia coli and mycete, infusorian etc. just can be by along reproductions for the course of disease
Device mucosa is up to be spread, spread through blood, through number of ways such as lymph diffusion, direct extensiones, the intrusion any position of cervix uteri and
It is inflamed.Cervicitis mainly shows as cervical erosion, cervical mucous membrane polyp, cervix uteri hypertrophy and nabothian cysts
Deng, can exist simultaneously, also can both or individualism.Cervical erosion is formed the most in the following way: when cervix uteri is long-term
When being immersed in Alkaline Secretion thing, squamous epithelial cancer the most gradually comes off, instead columnar epithelium, it is seen that upper small subcutaneous vessels appear and in
Existing cerise, claims pure cervical erosion；For a long time it, glandular epithelium hyperplasia, and with stroma hypertrophy in various degree, and
Present the outward appearance that graininess is uneven, claim granular pattern rotten to the corn；, nipple-like elevation occurs later hypertrophy due to more very, claim nipple
Type is rotten to the corn.Cervical erosion is a kind of modal chronic cervicitis, is generally divided into III degree: I degree refers to that rotten to the corn area accounts for whole palace
Within the 1/3 of neck area, II degree refers to that, between 1/3～2/3 that rotten to the corn area accounts for whole cervix uteri area, III degree refers to rotten to the corn face
Amass and account for more than the 2/3 of whole cervix uteri area.Cervical erosion is married femle commonly encountered diseases, be the most all by childbirth, miscarriage or
Operation technique damage cervix uteri, and puerperal, menstrual period unhygienic, unclean sexual life and antibacterial infect and cause, and shows as
Leucorrhoea grow in quantity, yellow skin, matter thickness, occur that purulent leukorrhea, sanguinous leukorrhea, abnormal flavour of leucorrhea, the soreness of waist, stomachache and hypogastric region heavily fall once in a while
Sense, some waist and sacrum pain, dysmenorrhea, sexual life also can cause contact bleeding, frequent micturition, urgent micturition, dysurea, the sometimes sense of secondary urinary tract
Dye.
Treatment cervicitis, uses the general cutter of power, cervix uteri ultrasonic therapeutic etc. at present, and the most both advantageous and disadvantageous, curative effect is not cut, and has
Certain side effect and risk, cause misery in various degree and financial burden to patient.In Drug therapy the most general
Use antibiotic or/and sulfa drugs treatment cervical erosion, as ticarcillin sodium and clavulanate potassium, ticarcillin, aztreonam,
Cefoperazone, kanamycin, sulfamethoxazole, ampicillin, carbenicillin etc..Using above-mentioned therapy, its major defect is
Western medicine untoward reaction is many, and along with the appearance of fastbacteria, treatment difficulty is increasing.
Prior art has attempted using treatment by Chinese herbs cervicitis and cervical erosion, as CN 102743590 B is open
A kind of cflush agent treating erosive type chronic cervicitis and preparation method thereof, this case takes Herba Verbenae, Herba Galii Teneri, anise
Lotus, Radix Wikstroemae, Rhizoma Saururi (Herba Saururi), Radix Berberidis, Folium Isatidis, Herba Euphoubiae Hirtae, Herba Lysimachiae, Radix et Rhizoma Rohdeae Japonicae, Herba Asteris Ageratoidis, Radix Sophorae Tonkinensis, mountain are kind
Aunt, Herba Senecionis Scandentis, Herba Lycopodii serrati, Radix Stephaniae Japonicae, Herba Euphorbiae Thymifoliae, Radix et Rhizoma Thalictri, Herba Portulacae, Folium Coriariae Sinicae, Herba Solani Surattensis, Radix Scutellariae, Rhizoma Coptidis, Cortex Phellodendri,
Above 29 taste medicines are put in water and are soaked by Herba Sidae Rhombifoliae, Cortex Ilicis Rotundae, Radix Stellariae, Semen Iridis and Radix Glycyrrhizae, and then slow fire is fried, filter
Removing slag, fried medicinal liquid is the cflush agent for the treatment of erosive type chronic cervicitis.CN103181950A discloses one
The Chinese medicine for the treatment of cervical erosion, it is to form with Realgar, catechu, Borneolum Syntheticum, Natrii Sulfas.CN101919991B discloses a kind of anti-
Pharmaceutical composition controlling cervical cancer and preparation method thereof, the crude drug of this pharmaceutical composition consists of Flos Lonicerae, Rhizoma Curcumae, Fructus Forsythiae, Wu
Centipede, Radix Arnebiae (Radix Lithospermi) and Cortex Phellodendri, first carry volatile oil in preparation method by Rhizoma Curcumae and Fructus Forsythiae, and raw material Flos Lonicerae carries with Scolopendra water, and raw material is yellow
Cypress and Radix Arnebiae (Radix Lithospermi) alcohol extraction, extracting solution is concentrated, be dried prepared medicated powder, mixes with volatile oil, is further processed into clinically-acceptable
Exterior-applied formulation.Inventor is found by research, and compositions disclosed in CN101919991B is due to prescription compatibility and preparation technology etc.
Reason, antiinflammatory action can not reach actual requirement, such as this patent extract Flos Lonicerae operation in, use water extraction, temperature
Higher, and temperature is not tolerated by Flos Lonicerae principle active component chlorogenic acid.Therefore, this area needs exploitation antiinflammatory action badly more
By force, better pharmaceutical composition.
Summary of the invention
It is an object of the invention to prevent and treat disclosed in CN101919991B cervical cancer pharmaceutical composition suppository and
On the basis of preparation method, formed by optimizing materials medicine, change preparation method, it is provided that a kind of new treatment inflammation is (such as uterus
Neck is scorching) pharmaceutical composition.
Another object of the present invention is to provide the preparation method of described pharmaceutical composition.
It is still another object of the present invention to provide described pharmaceutical composition in preparation for treating inflammation, such as cervicitis
Medicine in purposes.
For achieving the above object, on the one hand, the present invention provides a kind of pharmaceutical composition treating cervicitis, this medicine group
Compound includes Oleum Curcumae, fine powder and pharmaceutically acceptable adjuvant；
Described Oleum Curcumae and described fine powder are prepared through following steps by the crude drug including following weight portion:
Flos Lonicerae 5～25 weight portion, Fructus Forsythiae 5～25 weight portion, Cortex Phellodendri 5～25 weight portion, Radix Arnebiae (Radix Lithospermi) 5～25 weight portion, cowherb
Art 10～40 weight portion, Scolopendra 1～10 weight portion, Pseudobulbus Bletillae (Rhizoma Bletillae) 1～10 weight portion, Galla Chinensis 5～20 weight portion；
Described step includes:
Taking Rhizoma Curcumae and add the water of 5～10 times of weight, soaked overnight, extraction volatile oil 5～10 hours, this volatile oil is described
Oleum Curcumae, extracts the medical filtration after volatile oil and obtains extracting solution a；
After Cortex Phellodendri, Flos Lonicerae and Radix Arnebiae (Radix Lithospermi) being mixed, add the second that volume fraction is 50%～90% of 5～10 times of weight
Alcohol, reflux, extract, 1～5 times, each 1～3 hour, merge ethanol extract, remove ethanol, obtain extracting solution b；
After Scolopendra, Fructus Forsythiae, Galla Chinensis and Pseudobulbus Bletillae (Rhizoma Bletillae) are mixed, add the water of 5～20 times of weight, extract 1～5 time, each 1～
3 hours collecting decoctions, filter to obtain extracting solution c；
Extracting solution a, extracting solution b and extracting solution c are merged, concentrates, dry, pulverize to obtain described fine powder.
The technical scheme is that prevent and treat disclosed in CN101919991B cervical cancer pharmaceutical composition suppository and
On the basis of preparation method, being obtained by feed change pharmacopoeia class and Optimization of preparation, made pharmaceutical composition can
More effectively treat cervicitis.As a example by the extraction of wherein Flos Lonicerae, Cortex Phellodendri and Radix Arnebiae (Radix Lithospermi), in the traditional Chinese medical science prescription of the present invention, gold
Flos Lonicerae is monarch drug, ministerial drug in Cortex Phellodendri and the Radix Arnebiae (Radix Lithospermi) side of being, Flos Lonicerae main attack heat-clearing and toxic substances removing, Cortex Phellodendri, Radix Arnebiae (Radix Lithospermi) boosting Flos Lonicerae heat clearing away it
Power, has the effect of removing heat from blood, dampness concurrently, and three's mixed extraction is easy to the dissolution simultaneously of close functional component, reduces job step, and increase carries
Take active constituent content in thing；Meanwhile, to use finite concentration ethanol close with active component physicochemical property by it for the present invention
Ministerial drug Cortex Phellodendri, Radix Arnebiae (Radix Lithospermi) united extraction, it is to avoid the temperature destruction to effective ingredient.In the present invention, monarch drug in the Fructus Forsythiae side of being, enters
The fruit of medicine contains betulic acid, ursolic acid, oleanolic acid, arctiin, martairesinol, Fructus Forsythiae aglycon, forsythol, Fructus Forsythiae
The compound such as glycosides, Fructus Forsythiae ester glycoside.Forsythia Suspensa Seeds contains volatile oil, considers the interaction between medicine simultaneously and combines prescription Chinese medicine
The physicochemical property of effective ingredient contained by material, by Fructus Forsythiae, Pseudobulbus Bletillae (Rhizoma Bletillae), that Galla Chinensis merges water extraction with Scolopendra is the most reasonable.
Prescription of the present invention adds Galla Chinensis and Pseudobulbus Bletillae (Rhizoma Bletillae) two taste medical material, on the one hand increases this two tastes medicine and improves antiinflammatory work
Property, after on the other hand increasing this two tastes medicine, by the inventive method gained pharmaceutical composition, there is astriction, wound can be effectively improved
The symptoms such as the inflammatory exudation in face, prevent hemorrhage so that the present composition is particularly conducive to make exterior-applied formulation.Additionally, add
This two tastes medicine also can strengthen antivirus action and effectively prevent the generation of cervical cancer.
According to specific embodiments of the present invention, in pharmaceutical composition of the present invention, described crude drug is concrete
For: Flos Lonicerae 13.8 weight portion, Fructus Forsythiae 13.8 weight portion, Cortex Phellodendri 13.8 weight portion, Radix Arnebiae (Radix Lithospermi) 13.8 weight portion, Rhizoma Curcumae 27.6 weight
Part, Scolopendra 4.2 weight portion, Pseudobulbus Bletillae (Rhizoma Bletillae) 4.8 weight portion, Galla Chinensis 8.1 weight portion.
According to specific embodiments of the present invention, in pharmaceutical composition of the present invention, described crude drug is concrete
For: Flos Lonicerae 10 weight portion, Fructus Forsythiae 5 weight portion, Cortex Phellodendri 5 weight portion, Radix Arnebiae (Radix Lithospermi) 10 weight portion, Rhizoma Curcumae 20 weight portion, Scolopendra 5 weight
Part, Pseudobulbus Bletillae (Rhizoma Bletillae) 5 weight portion, Galla Chinensis 5 weight portion.
According to specific embodiments of the present invention, in pharmaceutical composition of the present invention, described crude drug is concrete
For: Flos Lonicerae 15 weight portion, Fructus Forsythiae 15 weight portion, Cortex Phellodendri 15 weight portion, Radix Arnebiae (Radix Lithospermi) 15 weight portion, Rhizoma Curcumae 30 weight portion, Scolopendra 5 weight
Amount part, Pseudobulbus Bletillae (Rhizoma Bletillae) 5 weight portion, Galla Chinensis 10 weight portion.
According to specific embodiments of the present invention, in pharmaceutical composition of the present invention, described crude drug is concrete
For: Flos Lonicerae 15 weight portion, Fructus Forsythiae 10 weight portion, Cortex Phellodendri 10 weight portion, Radix Arnebiae (Radix Lithospermi) 15 weight portion, Rhizoma Curcumae 35 weight portion, Scolopendra 10
Weight portion, Pseudobulbus Bletillae (Rhizoma Bletillae) 10 weight portion, Galla Chinensis 10 weight portion.
According to specific embodiments of the present invention, in pharmaceutical composition of the present invention, described step includes:
Taking Rhizoma Curcumae and add the water of 8 times of weight, soaked overnight, extract volatile oil 8 hours, this volatile oil is described Oleum Curcumae,
Extract the medical filtration after volatile oil and obtain extracting solution a；
After Cortex Phellodendri, Flos Lonicerae and Radix Arnebiae (Radix Lithospermi) being mixed, adding 8 times of weight volume fractions is the ethanol of 70%, reflux, extract, 2
Secondary, each 1.5 hours, merge ethanol extract, remove ethanol, obtain extracting solution b；
After Scolopendra, Fructus Forsythiae, Galla Chinensis and Pseudobulbus Bletillae (Rhizoma Bletillae) being mixed, add 10 times of weight water, extract 3 times, within each 1.5 hours, merge
Decocting liquid, filters to obtain extracting solution c；
Extracting solution a, extracting solution b and extracting solution c are merged, concentrates, dry, pulverize to obtain described fine powder.
On the other hand, present invention also offers the preparation method of described pharmaceutical composition, the method includes:
Take Rhizoma Curcumae and add the water of 5～10 times of weight, soaked overnight, extract 5～10 hours, obtain described Oleum Curcumae, extract cowherb
Medical filtration after art oil obtains extracting solution a；
After Cortex Phellodendri, Flos Lonicerae and Radix Arnebiae (Radix Lithospermi) being mixed, add the ethanol that 5～10 times of weight volume fractions are 50%～90%,
Reflux, extract, 1～5 times, each 1～3 hour, merge ethanol extract, removes ethanol and obtains extracting solution b；
After Scolopendra, Fructus Forsythiae, Galla Chinensis and Pseudobulbus Bletillae (Rhizoma Bletillae) are mixed, add 5～20 times of weight water, extract 1～5 time, each 1～3
Hour collecting decoction, filters to obtain extracting solution c；
Extracting solution a, extracting solution b and extracting solution c are merged, concentrates, dry, pulverize into described fine powder；
Described fine powder, described Oleum Curcumae and pharmaceutically acceptable adjuvant are mixed, prepares described pharmaceutical composition.
Pharmaceutical composition of the present invention can use pharmaceutical methods conventional in pharmaceutics by described fine powder, described Rhizoma Curcumae
Oily and pharmaceutically acceptable adjuvant mixing, is prepared as required Chinese medicine preparation.
On the other hand, the present invention also provides for a kind of pharmaceutical preparation, and it is made with pharmaceutical composition of the present invention
Dosage form, specifically, this pharmaceutical preparation is with Oleum Curcumae described in pharmaceutical composition of the present invention and described fine powder
Add the exterior-applied formulation that pharmaceutically acceptable adjuvant is prepared from；Preferably, described pharmaceutical preparation be suppository, effervescent,
Spray, aerosol or unguentum.
According to specific embodiments of the present invention, pharmaceutical preparation of the present invention is suppository.Preferably, this suppository also may be used
Including: glyceryl monostearate, stearic acid, mixed fatty glycerides 36 type, ethyl hydroxybenzoate and propylene glycol.
Can be prepared as follows obtaining containing the as above suppository of the present invention of adjuvant:
Glyceryl monostearate, stearic acid and mixed fatty glycerides 36 type are mixed, after melting at 60～65 DEG C, adds
Enter medicated powder of the present invention and make the medicinal liquid containing Chinese medicine extract, it is preferable that this medicated powder is ground into fine powder in advance；By oxybenzene
Ethyl ester joins after dissolving in propylene glycol, adds Oleum Curcumae and makes the medicinal liquid containing Oleum Curcumae, stirs；Treat containing Chinese medicine extract
Fluid temperature when being down to 40 ± 2 DEG C, add the medicinal liquid containing Oleum Curcumae, stir, be poured in bolt mould, cooling, make bolt
Agent.
On the other hand, present invention also offers described pharmaceutical composition or described pharmaceutical preparation in preparation for treating
Application in the medicine of inflammation；Preferably, described inflammation is cervicitis.
In sum, the present invention is preventing and treating pharmaceutical composition suppository and the preparation thereof of cervical cancer disclosed in CN101919991B
On the basis of method, formed by optimizing materials medicine, change preparation method, it is provided that a kind of have good treatment inflammation (spy
Not cervicitis) pharmaceutical composition.Specifically, the present invention has a following Advantageous Effects:
(1) present invention consists of optimizing materials medicine, changes preparation technology and obtains one relatively CN101919991B antiinflammatory
Better pharmaceutical composition.
(2) present invention is by by Flos Lonicerae, Cortex Phellodendri and Radix Arnebiae (Radix Lithospermi) mixed extraction, it is simple to the dissolution simultaneously of close functional component, subtracts
Few job step, increases active constituent content in extract.Meanwhile, certain density ethanol extraction is used, it is to avoid use water extraction
The too high destruction to effective ingredient of Shi Wendu.
(3) present invention is by Fructus Forsythiae and adjuvant drug Galla Chinensis, Pseudobulbus Bletillae (Rhizoma Bletillae), Scolopendra united extraction, can guarantee that antimicrobial component dissolution, strengthens
This medicine anti-inflammatory activity.
(4) prescription of the present invention adds Galla Chinensis and Pseudobulbus Bletillae (Rhizoma Bletillae) two taste medical material, while improving anti-inflammatory activity, on the one hand increases
Add this two tastes medicine and add anti-inflammatory activity, on the other hand improve the astriction of pharmaceutical composition, can more effectively improve wound surface
The symptom such as inflammatory exudation, prevent hemorrhage.Also can strengthen antivirus action additionally, add this two tastes medicine and effectively prevent cervix uteri
The generation of cancer.
Detailed description of the invention
In order to the technical characteristic of the present invention, purpose and beneficial effect are more clearly understood from, in conjunction with being embodied as
Technical scheme is carried out described further below by example, it should be understood that these embodiments be merely to illustrate the present invention rather than
Limit the scope of the present invention.The step mentioned the most in detail in each embodiment all can be carried out according to the routine operation of art.
Embodiment prepared by embodiment 1 suppository
The present embodiment crude drug consists of:
Cortex Phellodendri 3.428kg is (about for Flos Lonicerae 3.428kg (about 13.8 weight portion) Fructus Forsythiae 3.428kg (about 13.8 weight portion)
13.8 weight portions) Scolopendra 1.028kg is (about for Radix Arnebiae (Radix Lithospermi) 3.428kg (about 13.8 weight portion) Rhizoma Curcumae 6.856kg (about 27.6 weight portion)
4.2 weight portions) Pseudobulbus Bletillae (Rhizoma Bletillae) 1.2kg (about 4.8 weight portion) Galla Chinensis 2kg (about 8.1 weight portion).
The crude drug of above-mentioned weight is made through following steps the suppository of described pharmaceutical composition:
Take Rhizoma Curcumae and add the water of 8 times of weight, soaked overnight, extract volatile oil 8 hours, obtain Oleum Curcumae, after extracting volatile oil
Medical filtration obtain extracting solution a；
After Cortex Phellodendri, Flos Lonicerae and Radix Arnebiae (Radix Lithospermi) being mixed, adding 8 times of weight volume fractions is the ethanol of 70%, reflux, extract, 2
Secondary, each 1.5 hours, merge ethanol extract, remove ethanol, obtain extracting solution b；
After Scolopendra, Fructus Forsythiae, Galla Chinensis and Pseudobulbus Bletillae (Rhizoma Bletillae) being mixed, add 10 times of weight water, decoct and extract 3 times, each 1.5 little
Time, collecting decoction, obtain extracting solution c；
Extracting solution a, extracting solution b and extracting solution c are merged, concentrates, dry, pulverize, obtain fine powder；
By glyceryl monostearate 360g, stearic acid 180g, appropriate mixed fatty glycerides 36 type, mixing, in 60～
65 DEG C of melted substrate of making, addition gained fine powder, stir, standby；Weigh the ethyl hydroxybenzoate of 12g and join the third the two of 120g
In alcohol, 50 DEG C of heating for dissolving, add gained Oleum Curcumae, stir；When fluid temperature is down to 40 ± 2 DEG C, add the third two
Alcohol dissolves medicinal liquid, stirs, is poured in bolt mould, cools down 10～15 minutes in 5～8 DEG C, makes suppository.
Embodiment prepared by embodiment 2 suppository
The present embodiment crude drug consists of:
Flos Lonicerae 2.484kg (10 weight portion), Fructus Forsythiae 1.244kg (5 weight portion), Cortex Phellodendri 1.244kg (5 weight portion) are purple
Grass 2.484kg (10 weight portion), Rhizoma Curcumae 4.968kg (20 weight portion), Scolopendra 1.244kg (5 weight portion), Pseudobulbus Bletillae (Rhizoma Bletillae) 1.244kg (5
Weight portion), Galla Chinensis 1.244kg (5 weight portion).
The crude drug of above-mentioned weight is made through following steps the suppository of described pharmaceutical composition:
Take Rhizoma Curcumae and add the water of 5 times of weight, soaked overnight, extract volatile oil 10 hours, obtain Oleum Curcumae, after extracting volatile oil
Medical filtration obtain extracting solution a；
After Cortex Phellodendri, Flos Lonicerae and Radix Arnebiae (Radix Lithospermi) being mixed, adding 5 times of weight volume fractions is the ethanol of 50%, reflux, extract, 3
Secondary, each 2 hours, merge ethanol extract, remove ethanol, obtain extracting solution b；
After Scolopendra, Fructus Forsythiae, Galla Chinensis and Pseudobulbus Bletillae (Rhizoma Bletillae) being mixed, add 10 times of weight water, decoct and extract 3 times, each 1.5 little
Time, collecting decoction, obtain extracting solution c；
Extracting solution a, extracting solution b and extracting solution c are merged, concentrates, dry, pulverize, obtain fine powder；
By glyceryl monostearate 270g, stearic acid 135g, appropriate mixed fatty glycerides 36 type, mixing, in 60～
65 DEG C of heating make to melt completely, add gained fine powder, stir, standby；Weigh the ethyl hydroxybenzoate of 9g and join the third the two of 90g
In alcohol, 50 DEG C of heating for dissolving, it is subsequently adding gained Oleum Curcumae, stirs；When fluid temperature is down to 40 ± 2 DEG C, add
Propylene glycol dissolves medicinal liquid, stirs, is poured in bolt mould, cools down 10～15 minutes in 5～8 DEG C, makes suppository.
Embodiment 3 effervescent prepares embodiment
The present embodiment crude drug consists of:
Flos Lonicerae 3.728kg (15 weight portion), Fructus Forsythiae 3.728kg (15 weight portion), Cortex Phellodendri 3.728kg (15 weight portion),
Radix Arnebiae (Radix Lithospermi) 3.728kg (15 weight portion), Rhizoma Curcumae 7.452kg (30 weight portion), Scolopendra 1.244kg (5 weight portion), Pseudobulbus Bletillae (Rhizoma Bletillae) 1.244kg
(5 weight portion), Galla Chinensis 2.484kg (10 weight portion).
The crude drug of above-mentioned weight is made through following steps the effervescent of described pharmaceutical composition:
Take Rhizoma Curcumae and add the water of 8 times of weight, soaked overnight, extract volatile oil 8 hours, obtain Oleum Curcumae, after extracting volatile oil
Medical filtration obtain extracting solution a；
After Cortex Phellodendri, Flos Lonicerae and Radix Arnebiae (Radix Lithospermi) being mixed, adding 8 times of weight volume fractions is the ethanol of 70%, reflux, extract, 2
Secondary, each 1.5 hours, merge ethanol extract, remove ethanol, obtain extracting solution b；
After Scolopendra, Fructus Forsythiae, Galla Chinensis and Pseudobulbus Bletillae (Rhizoma Bletillae) being mixed, add 10 times of weight water, decoct and extract 3 times, each 1.5 little
Time, collecting decoction, obtain extracting solution c；
Extracting solution a, extracting solution b and extracting solution c are merged, concentrates, dry, pulverize, obtain fine powder；
Being dried 2 hours in 105 DEG C by citric acid, sodium carbonate, sodium bicarbonate are dried 2 hours in 120 DEG C, pulverize respectively
100 mesh sieves, airtight preservation；Stevioside, water soluble starch pulverized 100 mesh sieves respectively；PEG6000 pulverized 140 mesh sieves, dry
Dry device saves backup.Preparation process controls formulation environment temperature and humidity respectively 25 DEG C, less than 45%；Take gained thin
Powder, citric acid 305g mix homogeneously, then add the powders A of stevioside 37g mix homogeneously；By sodium bicarbonate 261g and sodium carbonate
392g, water soluble starch 500g mix homogeneously, obtain powder B；Powders A is mixed with powder B, adds PEG6000 50g, add institute
Obtain Oleum Curcumae fully to mix；Mixed-powder direct compression, prepares effervescent tablet.
Embodiment 4 spray prepares embodiment
The present embodiment crude drug consists of:
Flos Lonicerae 3.728kg (15 weight portion), Fructus Forsythiae 3.728kg (15 weight portion), Cortex Phellodendri 3.728kg (15 weight portion),
Radix Arnebiae (Radix Lithospermi) 3.728kg (15 weight portion), Rhizoma Curcumae 7.452kg (30 weight portion), Scolopendra 1.244kg (5 weight portion), Pseudobulbus Bletillae (Rhizoma Bletillae) 1.244kg
(5 weight portion), Galla Chinensis 2.484kg (10 weight portion).
The crude drug of above-mentioned weight is made through following steps the spray of described pharmaceutical composition:
Take Rhizoma Curcumae and add the water of 10 times of weight, soaked overnight, extract volatile oil 5 hours, obtain Oleum Curcumae, after extracting volatile oil
Medical filtration obtain extracting solution a；
After Cortex Phellodendri, Flos Lonicerae and Radix Arnebiae (Radix Lithospermi) being mixed, adding 10 times of weight volume fractions is the ethanol of 75%, reflux, extract, 2
Secondary, each 2 hours, merge ethanol extract, remove ethanol, obtain extracting solution b；
After Scolopendra, Fructus Forsythiae, Galla Chinensis and Pseudobulbus Bletillae (Rhizoma Bletillae) being mixed, add 15 times of weight water, decoct and extract 3 times, each 1 hour,
Collecting decoction, obtains extracting solution c；
Extracting solution a, extracting solution b and extracting solution c are merged, concentrate, dry, pulverize, obtain fine powder, add gained Oleum Curcumae,
And it is sequentially added into propylene glycol 900g, flavoring banana essence 160g, and mixing, then add ethanol to 40L, mixing, make spray.
Embodiment 5 aerosol prepares embodiment
The present embodiment crude drug consists of:
Flos Lonicerae 0.857g (about 13.8 weight portion) Fructus Forsythiae 0.857g (about 13.8 weight portion) Cortex Phellodendri 0.857g (about 13.8 weights
Amount part) Radix Arnebiae (Radix Lithospermi) 0.857g (about 13.8 weight portion) Rhizoma Curcumae 1.714g (about 27.6 weight portion) Scolopendra 0.257g (about 4.2 weight portion)
Pseudobulbus Bletillae (Rhizoma Bletillae) 0.3g (about 4.8 weight portion) Galla Chinensis 0.5g (about 8.1 weight portion).
The crude drug of above-mentioned weight is made through following steps the aerosol of described pharmaceutical composition:
Take Rhizoma Curcumae and add the water of 8 times of weight, soaked overnight, extract volatile oil 8 hours, obtain Oleum Curcumae, after extracting volatile oil
Medical filtration obtain extracting solution a；
After Cortex Phellodendri, Flos Lonicerae and Radix Arnebiae (Radix Lithospermi) being mixed, adding 8 times of weight volume fractions is the ethanol of 70%, reflux, extract, 2
Secondary, each 1.5 hours, merge ethanol extract, remove ethanol, obtain extracting solution b；
After Scolopendra, Fructus Forsythiae, Galla Chinensis and Pseudobulbus Bletillae (Rhizoma Bletillae) being mixed, add 10 times of weight water, decoct and extract 3 times, each 1.5 little
Time, collecting decoction, obtain extracting solution c；
Extracting solution a, extracting solution b and extracting solution c are merged, concentrate, dry, pulverize, obtain fine powder, add gained Oleum Curcumae,
Mixing, then adds appropriate amount of ethanol, mixing, and above-mentioned ethanol solution and dichlorodifluoromethane fill are made aerosol.
Embodiment prepared by embodiment 6 unguentum
The present embodiment crude drug consists of:
Flos Lonicerae 0.621g (10 weight portion), Fructus Forsythiae 0.311g (5 weight portion), Cortex Phellodendri 0.311g (5 weight portion), Radix Arnebiae (Radix Lithospermi)
0.621g (10 weight portion), Rhizoma Curcumae 1.242g (20 weight portion), Scolopendra 0.311g (5 weight portion), Pseudobulbus Bletillae (Rhizoma Bletillae) 0.311g (5 weight
Part), Galla Chinensis 0.311g (5 weight portion).
The crude drug of above-mentioned weight is made through following steps the unguentum of described pharmaceutical composition:
Take Rhizoma Curcumae and add the water of 8 times of weight, soaked overnight, extract volatile oil 6 hours, obtain Oleum Curcumae, after extracting volatile oil
Medical filtration obtain extracting solution a；
After Cortex Phellodendri, Flos Lonicerae and Radix Arnebiae (Radix Lithospermi) being mixed, adding 8 times of weight volume fractions is the ethanol of 70%, reflux, extract, 2
Secondary, each 3 hours, merge ethanol extract, remove ethanol, obtain extracting solution b；
Take Scolopendra, Fructus Forsythiae, Galla Chinensis and Pseudobulbus Bletillae (Rhizoma Bletillae) and add 12 times of weight water, decoct and extract 2 times, each 2 hours, merge and decoct
Liquid, obtains extracting solution c；
Extracting solution a, extracting solution b and extracting solution c are merged, concentrates, dry, pulverize, obtain fine powder；
Taking gained fine powder to be dispersed in water, adding 0.2g citric acid, stirring, it is thus achieved that the first phase, by 5g sodium polyacrylate
The most swelling with water, obtain the second phase, 0.4g oxybenzene ethyl ester is joined in 20g rubber, adds gained Oleum Curcumae abundant
Stirring, it is thus achieved that third phase, is sufficiently mixed the second phase and third phase, then is added to wherein make unguentum by first.
Embodiment 7 antiinflammatory is tested
1. on the impact that the experimental rat foot sole of the foot is swollen
Experiment material: animal Wistar male rat, purchased from hospital general of Nanjing Military Command, the quality certification: SCXK (Soviet Union) 2003-
0004.Aspirin suppositories, Xi'an Hengtongguanghua Pharmaceutical Co., Ltd, lot number: 20104082.Treat I group and use medicine of the present invention
The pharmaceutical composition suppository that embodiment 1 prepares.Treat II group and use pharmaceutical composition (silver disclosed in CN 101919991 B
Flower 3kg, Rhizoma Curcumae 6kg, Fructus Forsythiae 3kg, Scolopendra 3kg, Radix Arnebiae (Radix Lithospermi) 3kg, Cortex Phellodendri 3kg；Take crude drug Rhizoma Curcumae and Fructus Forsythiae adds 8 times of weight
Water, extracts 8 hours, obtains volatile oil 25-30 μ l and extracting solution a；Take crude drug Flos Lonicerae and Scolopendra adds the water of 8 times of weight, decoct 2
Secondary, each 1 hour, solution b must be extracted；Take crude drug Cortex Phellodendri and Radix Arnebiae (Radix Lithospermi), add 70% ethanol extraction 2 times, reclaim ethanol, obtain extraction
Liquid c；Merging above extracting solution a, b and c, concentrate, be dried, obtain medicated powder, flour extraction is 12%；Take semi-synthetic fatty acid ester 40g, take
Above-mentioned medicated powder 8g, then spray into above-mentioned gained volatile oil, prepare suppository according to a conventional method).
Experimental technique: take Wistar male rat 120, body weight 130～150g, be randomly divided into 4 groups, i.e. treat I group, control
Treat II group, compare I group (model group) and II group (aspirin suppositories group) of comparison, treat I group, treat II group and give relative medicine bolt
Agent, compares II group and gives positive drug suppository, compares I group to same volume bare substrate suppository.After 15min, to all experimental rats
From the right metapedes centre of the palm to ankle joint subcutaneous injection 10% fresh egg white 0.1ml.From injection 0.5,1,3,4h time respectively with foot sole of the foot capacity
Device measures the swelling of the ankle joint of rat injection medicine, and acquired results is as shown in table 1, as it can be seen from table 1 each administration group is given
After medicine, toes swelling degree is all obviously reduced, and wherein treats I, II group and is proportionate with the time, and treats I during identical time point
The degree of group foot swelling is significantly less than treatment II group.
Table 1 treatment group and the matched group impact on experimental rat pedal swelling
Note: compare with compareing II group, *: P < 0.05, * *: P < 0.01
2. the impact on experiment mice auricle capillary permeability
Experiment material: Male Kunming strain mice, purchased from hospital general of Nanjing Military Command, the quality certification: SCXK (Soviet Union) 2003-0004.
Aspirin suppositories, Xi'an Hengtongguanghua Pharmaceutical Co., Ltd, lot number: 20104082.Treat I group and use Medications Example of the present invention
The pharmaceutical composition suppository that 2 prepare.Treat II group use pharmaceutical composition Flos Lonicerae 3kg disclosed in CN 101919991 B,
Rhizoma Curcumae 6kg, Fructus Forsythiae 3kg, Scolopendra 3kg, Radix Arnebiae (Radix Lithospermi) 3kg, Cortex Phellodendri 3kg；Take crude drug Rhizoma Curcumae and Fructus Forsythiae adds the water of 8 times of weight, extract 8
Hour, obtain volatile oil 25-30 μ l and extracting solution a；Take crude drug Flos Lonicerae and Scolopendra adds the water of 8 times of weight, decoct 2 times, each 1 little
Time, solution b must be extracted；Take crude drug Cortex Phellodendri and Radix Arnebiae (Radix Lithospermi), add 70% ethanol extraction 2 times, reclaim ethanol, obtain extracting solution c；Merge with
Upper extracting solution a, b and c, concentrate, and is dried, obtains medicated powder, and flour extraction is 12%；Take semi-synthetic fatty acid ester 40g, take above-mentioned medicated powder
8g, then spray into above-mentioned gained volatile oil, prepare suppository according to a conventional method).
Experimental technique: take Male Kunming strain mice 100, body weight 18～22g, be randomly divided into 5 groups, i.e. compares I group of (blank
Matched group), compare II group (model group), compare III group (aspirin suppositories group), treat I group, treat II group.Treat I group, treatment
II group gives suppository；Compare I, II group to same volume bare substrate suppository.After 0.5h give comparison II, compare III group, treat I group,
Treat II group of mouse right ear exterior feature proximal edge and drip 2 melted paraxylenes.Take off Mice Auricle with the card punch of diameter 8mm after 15min and drip two
Organizing at toluene swelling and at I group of nearly edge of mouse right ear of comparison, weigh, acquired results is as shown in table 2, from Table 2, it can be seen that
Compareing II group and compare with compareing I group, mouse ear sheet weight, apparently higher than compareing I group, shows modeling success；Treatment group with compare II
Group compares, and mouse ear sheet weight all reduces；Wherein treat I group to reduce substantially, and with compare I group without significant difference, show to treat I
Suppository of the present invention in group can significantly reduce mouse ear sheet weight, reduces Mice Auricle capillary permeability, and recovers to just
In the range of Chang.
Table 2 treatment group and the matched group impact on Mice Auricle capillary permeability
| Group | Dosage (g/kg) | Number of animals (only) | Mouse ear sheet weight (mg) |
| Compare I group | - | 20 | 14.21±6.39## |
| Compare II group | - | 20 | 18.60±2.80** |
| Compare III group | 0.5 | 20 | 14.10±3.80## |
| Treat I group | 0.8 | 20 | 13.94±4.51## |
| Treat II group | 0.8 | 20 | 15.90±5.83# |
Note: compare *: P < 0.05, * *: P < 0.01 with compareing I group；#:P < 0.05, ##:P < 0.01 is compared with compareing II group
3. Pyrogentisinic Acid causes the impact of cervicitis rat
Experiment material: female sd inbred rats: provided by hospital of Nanjing Military Command Experimental Animal Center, the quality certification number: SCXK (army)
2007-012；Xiaomi vagina effervescent tablet, overseas pharmacy, lot number: 20081001, treat I group and use Medications Example 1 of the present invention to make
The standby pharmaceutical composition suppository obtained.Treat II group and use pharmaceutical composition Flos Lonicerae 3kg, Rhizoma Curcumae disclosed in CN 101919991 B
6kg, Fructus Forsythiae 3kg, Scolopendra 3kg, Radix Arnebiae (Radix Lithospermi) 3kg, Cortex Phellodendri 3kg；Take crude drug Rhizoma Curcumae and Fructus Forsythiae adds the water of 8 times of weight, extract 8 little
Time, obtain volatile oil 25-30 μ l and extracting solution a；Take crude drug Flos Lonicerae and Scolopendra adds the water of 8 times of weight, decoct 2 times, each 1 little
Time, solution b must be extracted；Take crude drug Cortex Phellodendri and Radix Arnebiae (Radix Lithospermi), add 70% ethanol extraction 2 times, reclaim ethanol, obtain extracting solution c；Merge with
Upper extracting solution a, b and c, concentrate, and is dried, obtains medicated powder, and flour extraction is 12%；Take semi-synthetic fatty acid ester 40g, take above-mentioned medicated powder
8g, then spray into above-mentioned gained volatile oil, prepare suppository according to a conventional method).
Experimental technique: take Healthy female SD rat 50, body weight 180～220g.Being randomly divided into 5 groups, it is the most right to be respectively
According to group, model group, positive controls (Xiaomi vagina effervescent tablet), treat I group, treat II group.Replicate rat cervicitis model: use
1ml syringe inserts at the about 1cm of SD rat vagina depths gently, injects 25% Hydroxybenzene mucilage 0.1ml/100g, stop in situ 1～
2min, prevents liquid spilling 1 time every other day, totally 5 times.Treating I group, treat II group and give suppository, positive controls disappears rotten cloudy
Road effervescent tablet, Normal group and model group are to same volume bare substrate suppository.It is administered once daily, successive administration 14d.From making
Mould starts, and perusal every day rat vagina collar extension is with or without red and swollen, congested and purulent secretion.After last is administered, 1h weighs,
Abdominal aortic blood separation Virus monitory inflammatory cytokine IL-1 β, PGE2, the content of TNF-α, take vagina and weigh calculated weight
Index, then take the standby inspection of a block organization, fixing with 10% neutral formalin, paraffin embedding, section, HE dyes, and om observation vagina is extremely
Uterus histomorphology change and mucosa, mucosa under the morphologic inflammatory of interstitial change, result as shown in table 3, table 4, table 5, from
Can be seen that model group rats vagina coefficient substantially to increase with normal group in table to compare has significant difference (P < 0.01)；With model
Group compares, and treats I group, treats II group of rat vagina coefficient reduction (P < 0.01)；Phenol causes vagina and cervicitis rat model group
In the cervical epithelial tissue degeneration necrosis of rat, cell infiltration, uterine cavity, inflammatory exudate compares with normal group and has significance
Raise (P < 0.01).Treat I group, treat inflammatory exudate in II group of cervical epithelial tissue degeneration necrosis, cell infiltration, uterine cavity
Substantially reduce, compare with model group and be respectively provided with significant difference (P < 0.01)；Comparing with normal group, rat model serum inflammatory is thin
Intracellular cytokine IL-1 β, PGE2, the content significantly raised (P < 0.01) of TNF-α；Compare with model group, positive controls, treat I group
Can obviously reduce the content (P < 0.01, P < 0.05) of cytokine IL-1 β, PGE2, TNF-α, treat II group can reduce cell because of
The content (P < 0.05) of sub-PGE2.
Table 3 treatment group, matched group and positive group Pyrogentisinic Acid cause the impact of cervicitis rat vagina coefficient
Note: compare with normal group△△: P < 0.01；Compare with model group**: P < 0.01
Table 4 medicine of the present invention Pyrogentisinic Acid causes cervicitis rat vagina and the impact of cervicitis model pathology
Note: compare with normal group△△: P < 0.01；Compare with model group**: P < 0.01
Table 5 treatment group, matched group and positive group Pyrogentisinic Acid cause the impact of cervicitis rat blood serum inflammatory cytokine
| Group | Dosage (g/kg) | IL-1β(pg/ml) | TNF-α(pg/ml) | PGE2(pg/ml) |
| Normal group | - | 17.63±5.27 | 48.13±6.60 | 12.83±2.64 |
| Model group | - | 42.67±13.51△△ | 58.88±13.00△△ | 20.55±4.69△△ |
| Positive group | 0.4 | 20.55±6.57** | 53.49±11.24* | 14.96±3.47** |
| Treat I group | 0.56 | 23.15±9.44** | 54.36±11.51* | 15.50±2.33** |
| Treat II group | 0.56 | 32.00±14.95 | 58.22±9.53 | 16.10±2.76* |
Note: compare with normal group△△: P < 0.01；Compare with model group**: P < 0.01
4. conclusion
By pharmaceutical composition of the present invention, Ovum Gallus domesticus album is caused the impact of experimental rat pedal swelling, xylol causes experiment mice
The impact of auricle capillary permeability and Pyrogentisinic Acid cause the influence research result of cervicitis rat and show: drug regimen of the present invention
Thing has good antiinflammatory action, can be used for treating cervicitis.
Finally illustrate: above example is merely to illustrate implementation process and the feature of the present invention, and unrestricted is sent out
Bright technical scheme, although being described in detail the present invention with reference to above-described embodiment, those of ordinary skill in the art should
Work as understanding: still the present invention can be modified or equivalent, without departing from the spirit and scope of the present invention any
Amendment or local are replaced, and all should contain in the middle of protection scope of the present invention.
Claims (9)
1. treating a pharmaceutical composition for cervicitis, this pharmaceutical composition includes Oleum Curcumae, fine powder and pharmaceutically acceptable
Adjuvant；
Described Oleum Curcumae and described fine powder are prepared as follows by the crude drug including following weight portion:
Flos Lonicerae 5～25 weight portion, Fructus Forsythiae 5～25 weight portion, Cortex Phellodendri 5～25 weight portion, Radix Arnebiae (Radix Lithospermi) 5～25 weight portion, Rhizoma Curcumae 10
～40 weight portions, Scolopendra 1～10 weight portion, Pseudobulbus Bletillae (Rhizoma Bletillae) 1～10 weight portion, Galla Chinensis 5～20 weight portion；
Described step includes:
Taking Rhizoma Curcumae and add the water of 5～10 times of weight, soaked overnight, extraction volatile oil 5～10 hours, this volatile oil is described Rhizoma Curcumae
Oil, extracts the medical filtration after volatile oil and obtains extracting solution a；
After Cortex Phellodendri, Flos Lonicerae and Radix Arnebiae (Radix Lithospermi) being mixed, add the ethanol that volume fraction is 50%～90% of 5～10 times of weight, return
Stream extracts 1～5 time, each 1～3 hour, merges ethanol extract, removes ethanol, obtain extracting solution b；
After Scolopendra, Fructus Forsythiae, Galla Chinensis and Pseudobulbus Bletillae (Rhizoma Bletillae) being mixed, adding the water of 5～20 times of weight, extract 1～5 time, each 1～3 is little
Time collecting decoction, filter to obtain extracting solution c；
Extracting solution a, extracting solution b and extracting solution c are merged, concentrates, dry, pulverize to obtain described fine powder.
Pharmaceutical composition the most according to claim 1, wherein, described crude drug is:
Flos Lonicerae 13.8 weight portion, Fructus Forsythiae 13.8 weight portion, Cortex Phellodendri 13.8 weight portion, Radix Arnebiae (Radix Lithospermi) 13.8 weight portion, Rhizoma Curcumae 27.6 weight
Amount part, Scolopendra 4.2 weight portion, Pseudobulbus Bletillae (Rhizoma Bletillae) 4.8 weight portion, Galla Chinensis 8.1 weight portion；Or
Flos Lonicerae 10 weight portion, Fructus Forsythiae 5 weight portion, Cortex Phellodendri 5 weight portion, Radix Arnebiae (Radix Lithospermi) 10 weight portion, Rhizoma Curcumae 20 weight portion, Scolopendra 5 weight
Amount part, Pseudobulbus Bletillae (Rhizoma Bletillae) 5 weight portion, Galla Chinensis 5 weight portion；Or
Flos Lonicerae 15 weight portion, Fructus Forsythiae 15 weight portion, Cortex Phellodendri 15 weight portion, Radix Arnebiae (Radix Lithospermi) 15 weight portion, Rhizoma Curcumae 30 weight portion, Scolopendra 5
Weight portion, Pseudobulbus Bletillae (Rhizoma Bletillae) 5 weight portion, Galla Chinensis 10 weight portion；Or
Flos Lonicerae 15 weight portion, Fructus Forsythiae 10 weight portion, Cortex Phellodendri 10 weight portion, Radix Arnebiae (Radix Lithospermi) 15 weight portion, Rhizoma Curcumae 35 weight portion, Scolopendra 10
Weight portion, Pseudobulbus Bletillae (Rhizoma Bletillae) 10 weight portion, Galla Chinensis 10 weight portion.
Pharmaceutical composition the most according to claim 1, wherein, described step includes:
Taking Rhizoma Curcumae and add the water of 8 times of weight, soaked overnight, extract volatile oil 8 hours, this volatile oil is described Oleum Curcumae, extracts
Medical filtration after volatile oil obtains extracting solution a；
After Cortex Phellodendri, Flos Lonicerae and Radix Arnebiae (Radix Lithospermi) being mixed, adding 8 times of weight volume fractions is the ethanol of 70%, reflux, extract, 2 times, often
Secondary 1.5 hours, merge ethanol extract, remove ethanol, obtain extracting solution b；
After Scolopendra, Fructus Forsythiae, Galla Chinensis and Pseudobulbus Bletillae (Rhizoma Bletillae) being mixed, add 10 times of weight water, extract 3 times, within each 1.5 hours, merge and decoct
Liquid, filters to obtain extracting solution c；
Extracting solution a, extracting solution b and extracting solution c are merged, concentrates, dry, pulverize to obtain described fine powder.
4. the preparation method of the pharmaceutical composition according to any one of claims 1 to 3, the method includes:
Taking Rhizoma Curcumae and add the water of 5～10 times of weight, soaked overnight, extraction volatile oil 5～10 hours, this volatile oil is described Rhizoma Curcumae
Oil, extracts the medical filtration after volatile oil and obtains extracting solution a；
After Cortex Phellodendri, Flos Lonicerae and Radix Arnebiae (Radix Lithospermi) being mixed, add the ethanol that 5～10 times of weight volume fractions are 50%～90%, backflow
Extract 1～5 time, each 1～3 hour, merge ethanol extract, remove ethanol and obtain extracting solution b；
After Scolopendra, Fructus Forsythiae, Galla Chinensis and Pseudobulbus Bletillae (Rhizoma Bletillae) are mixed, add 5～20 times of weight water, extract 1～5 time, each 1～3 hour
Collecting decoction, filters to obtain extracting solution c；
Extracting solution a, extracting solution b and extracting solution c are merged, concentrates, dry, pulverize into described fine powder；
Described fine powder, described Oleum Curcumae and pharmaceutically acceptable adjuvant are mixed, prepares described pharmaceutical composition.
5. a pharmaceutical preparation, it is with Oleum Curcumae described in the pharmaceutical composition according to any one of claims 1 to 3 and institute
State fine powder and add the exterior-applied formulation that pharmaceutically acceptable adjuvant is prepared from.
Pharmaceutical preparation the most according to claim 5, wherein, described pharmaceutical preparation is suppository, effervescent, spray, gas
Mist agent or unguentum.
Pharmaceutical preparation the most according to claim 6, wherein, described pharmaceutical preparation is suppository.
8. the pharmaceutical composition according to any one of claims 1 to 3 or the medicine system according to any one of claim 5～7
Agent is used for the application treating in the medicine of inflammation in preparation.
Application the most according to claim 8, wherein, described inflammation is cervicitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610516572.4A CN105999085B (en) | 2016-07-01 | 2016-07-01 | A kind of pharmaceutical composition and the preparation method and application thereof for treating cervicitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610516572.4A CN105999085B (en) | 2016-07-01 | 2016-07-01 | A kind of pharmaceutical composition and the preparation method and application thereof for treating cervicitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105999085A true CN105999085A (en) | 2016-10-12 |
| CN105999085B CN105999085B (en) | 2019-02-05 |
Family
ID=57106682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610516572.4A Active CN105999085B (en) | 2016-07-01 | 2016-07-01 | A kind of pharmaceutical composition and the preparation method and application thereof for treating cervicitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105999085B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101919991A (en) * | 2010-02-09 | 2010-12-22 | 金哲 | Drug composition for treating cervical cancer and preparation method thereof |
| CN103041283A (en) * | 2011-10-12 | 2013-04-17 | 薛晓鸥 | Externally-used traditional Chinese medicine composition for treating cervical HPV infection and preparation method thereof |
-
2016
- 2016-07-01 CN CN201610516572.4A patent/CN105999085B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101919991A (en) * | 2010-02-09 | 2010-12-22 | 金哲 | Drug composition for treating cervical cancer and preparation method thereof |
| CN103041283A (en) * | 2011-10-12 | 2013-04-17 | 薛晓鸥 | Externally-used traditional Chinese medicine composition for treating cervical HPV infection and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 刘等: "中药凝胶剂在宫颈炎中的应用进展", 《中医药学报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105999085B (en) | 2019-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103463297A (en) | Traditional Chinese medicine composition for treating eczema of scrotum as well as preparation method and use thereof | |
| CN102743662B (en) | Zhuang medicine preparation for treating gynecological inflammation and preparation method thereof | |
| CN101095923B (en) | Chinese traditional medicine for treating ectopic pregnancy | |
| CN104510853B (en) | A kind of Chinese medicinal effective-part composition for the treatment of dysmenorrhes and uses thereof | |
| CN104173858A (en) | Danefukang granules and preparation method thereof | |
| CN104524071A (en) | Pharmaceutical composition for treating primary renal disease and application thereof | |
| CN110368445A (en) | A kind of Chinese medicine composition and its preparation method and application for treating psoriasis | |
| CN100450517C (en) | Dysmenorrhea treating Chinese traditional medicine preparation | |
| CN1712047B (en) | Chinese medicinal composition for treating adenomyosis uteri | |
| CN107875211B (en) | Composition for treating ulcerative colitis and preparation method and application thereof | |
| CN104523603A (en) | Traditional Chinese medicine granules and preparation method and use thereof | |
| CN101264314A (en) | Medicaments assembly for clearing heat and detoxication, activating blood circulation and removing stasis, and diminishing inflammation and reducing pain | |
| CN101912586B (en) | Medicament for treating mammary gland hyperplasia and preparation method thereof | |
| CN103977106A (en) | Traditional Chinese medicine preparation for treating nephrotic syndrome and preparation method thereof | |
| CN105999085A (en) | Pharmaceutical composition for curing cervicitis and preparation method and application of pharmaceutical composition | |
| CN105770691A (en) | Medicinal preparation for treating cervical cancer and application thereof | |
| CN106421630A (en) | Radix Curcumae Aromaticae extract product, and preparation method and application thereof | |
| CN100409892C (en) | Externally applied medicament for treating hyperplasia of mammary glands and preparation method thereof | |
| CN104383349A (en) | Drug for postoperative recovery of bladder cancer and preparation method of drug for postoperative recovery of bladder cancer | |
| CN111658748A (en) | Composition for treating dysmenorrhea, oral preparation and application | |
| CN104274746B (en) | Pharmaceutical composition for treating pharyngitis | |
| CN103948899A (en) | Traditional Tibetan medicine for treating atrophic gastritis | |
| CN108354998B (en) | Extract for treating pelvic inflammation and preparation method thereof | |
| CN102319391A (en) | Chinese medicinal soft capsule for treating uterine fibroid and preparation method thereof | |
| CN106038802A (en) | Preparation method of traditional Chinese medicinal composition for treating premature ovarian failure of women and traditional Chinese medicinal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |